autologIX for Peripheral Nerve
“89% complete pain elimination sustained 5.4 years — beginning 2 weeks before reinnervation was possible (Kuffler 2026).”
The scientific rationale
Standard PRP concentrates platelets and their growth factors — PDGF, VEGF, TGF-beta. But the two growth factors most critical for peripheral nerve regeneration are plasma-derived, not platelet-derived, and standard PRP achieves zero enrichment of either.
IGF-1 is the Schwann cell survival factor (Syroid et al. 1999). In diabetic neuropathy, circulating IGF-1 is diminished and peripheral nerve IGF-1 mRNA is reduced — yet replacement of IGF-1 prevents neuropathy despite persistent hyperglycemia. Beitia et al. (2023) confirmed IGF-1 is the only growth factor correlated with cell proliferation in PRP and it does not correlate with platelet count. HGF activates repair Schwann cells through c-Met signaling and upregulates GDNF — the most potent motor neuron survival factor (Ko et al. 2018). HGF gene therapy (VM202) has received FDA RMAT designation for diabetic neuropathy, with Phase 2 data showing 48.4% of patients achieved 50% or greater pain reduction versus 17.6% placebo (P = 0.03).
autologIX enriches both IGF-1 and HGF through ultrafiltration, closing the neurotrophic gap that standard PRP cannot fill. The 15 kDa membrane retains all dimeric neurotrophins: NGF (26.5 kDa), BDNF (27 kDa), NT-3 (27.3 kDa). Platelets carry approximately 99% of peripheral BDNF. Concentrated fibrinogen provides a scaffold that binds at least 15 growth factors including BDNF and NT-3 for sustained delivery.
Three clinical anchors support PRP for nerve: carpal tunnel syndrome (9+ meta-analyses; PRP superior to corticosteroids at 6–12 months), diabetic neuropathy (17.7% NCV improvement — the largest for any injectable), and nerve injury repair (Kuffler 2026: 89% complete pain elimination sustained 5.4 years).
The AAOS 2024 guideline issued a strong recommendation against PRP for long-term CTS benefit. This must be disclosed: however, the evidence search ended November 2022, excluding six major post-2022 meta-analyses that unanimously favor PRP. The peer reviewer formally dissented.
Clinical studies investigating autologIX outcomes for peripheral nerve are in development.
Key published evidence
Fathallah et al. 2024 — Largest CTS synthesis (131 studies, 9,337 subjects). PRP significantly superior to corticosteroids for function (P < 0.00001), severity (P = 0.04), and pain (P = 0.007) at 6–12 months.
Kuffler et al. 2026 — 89% complete pain elimination sustained 5.4 years in nerve gap repair. Pain reduction at 2 weeks — before reinnervation. Experimental Biology and Medicine.
Elsayed et al. 2025 — DPN: tibial NCV improved 17.7% (P < 0.001). Control group deteriorated. Journal of Ultrasound.
Ko et al. 2018 — HGF activates repair Schwann cells via c-Met; upregulates GDNF. Scientific Reports.
Syroid et al. 1999 — IGF-1 promotes Schwann cell survival via autocrine/paracrine loop. Journal of Neuroscience.
Limitations
AAOS 2024 issued a strong recommendation against PRP for long-term CTS benefit (evidence cutoff November 2022; peer reviewer dissented). DPN evidence is limited to small studies from Egypt/Pakistan. Kuffler data is a case series from a single group. No autologIX-specific nerve data exist.
References
- Fathallah J et al. 2024. https://pubmed.ncbi.nlm.nih.gov/39360626/
- Kuffler DP et al. Exp Biol Med. 2026. https://www.ebm-journal.org/journals/experimental-biology-and-medicine/articles/10.3389/ebm.2026.10907/full
- Elsayed MA et al. J Ultrasound. 2025. https://link.springer.com/article/10.1007/s40477-025-01042-7
- Ko KR et al. Sci Rep. 2018;8:8592. https://pubmed.ncbi.nlm.nih.gov/29844434/
- Syroid DE et al. J Neurosci. 1999;19(6):2059-2068. https://pubmed.ncbi.nlm.nih.gov/10066259/
